Fmoc-(S)-3-amino-4-(2-naphthyl)-butyric acid | 1186216-21-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: Fmoc-(S)-3-amino-4-(2-naphthyl)-butyric acid
• 英文别名: (S)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-(naphthalen-2-yl)butanoic acid；(3S)-3-(9H-fluoren-9-ylmethoxycarbonylamino)-4-naphthalen-2-ylbutanoic acid
• CAS: 1186216-21-6
• 化学式: C₂₉H₂₅NO₄
• mdl: MFCD01861036
• 分子量: 451.522
• InChiKey: LQGDRWACMZMSCD-QFIPXVFZSA-N

物化性质

• 沸点：
  702.5±55.0 °C(Predicted)
• 密度：
  1.275±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.172
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  FMOC-(S)-3-氨基-4-(3-吡啶基)丁酸 、 Fmoc-(S)-3-amino-4-(2-naphthyl)-butyric acid 、 、 、 Fmoc-L-beta-高缬氨酸 、 Fmoc-L-beta-高异亮氨酸 、 (S)-6-Amino-3-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid 在 哌啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.23h， 生成
  参考文献：
  名称：

  Identification of a β3-peptide HIV fusion inhibitor with improved potency in live cells

  摘要：

  We recently reported a beta(3)-decapeptide, beta WWI-1, that binds a validated gp41 model in vitro and inhibits gp41-mediated fusion in cell culture. Here we report six analogs of beta WWI-1 containing a variety of non-natural side chains in place of the central tryptophan of the WWI-epitope. These analogs were compared on the basis of both gp41 affinity in vitro and fusion inibition in live, HIV-infected cells. One new beta(3)-peptide, beta WXI-a, offers a significantly improved CC50/EC50 ratio in the live cell assay. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.05.032

文献信息

• CONJUGATE-BASED ANTIFUNGAL AND ANTIBACTERIAL PRODRUGS
  申请人：Bapat Abhijit S.

  公开号：US20140364595A1

  公开（公告）日：2014-12-11

  The invention provides conjugate-based antifungal or antibacterial prodrugs formed by coupling at least one anti-fungal agent or antibacterial agent with at least one linker and/or carrier. The prodrugs are of formula: (i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; or (iv) (AFA) m″ -X, wherein: AFA is an antifungal agent or an antibacterial agent; L is a carrier; X is a linker; m ranges from 1 to 10; n ranges from 2 to 10; m′ is 1 to 10; p is 1 to 10; n′ is 1 to 10; and q is 1 to 10, provided that q′ and n are not both 1; and m″ is 1 to 10. The invention also provides nanoparticles comprising the conjugate-based prodrugs. Additionally, the invention also provides non-conjugated antifungal and antibacterial agents in the form of nanoparticles.

  该发明提供了由至少一种抗真菌剂或抗菌剂与至少一种连接剂和/或载体偶联形成的基于共轭的抗真菌或抗菌前药。这些前药的公式为：(i) (AFA) m -X-(L) n ; (ii) [(AFA) m′ -X] p -L; (iii) AFA-[X-(L) n′ ] q ; 或 (iv) (AFA) m″ -X，其中：AFA是抗真菌剂或抗菌剂；L是载体；X是连接剂；m范围从1到10；n范围从2到10；m′为1到10；p为1到10；n′为1到10；q为1到10，前提是q'和n不同时为1；m″为1到10。该发明还提供了包含基于共轭的前药的纳米粒子。此外，该发明还提供了以纳米粒子形式的非共轭抗真菌和抗菌剂。
• GRAMICIDIN A MUTANTS THAT FUNCTION AS ANTIBIOTICS WITH IMPROVED SOLUBILITY AND REDUCED TOXICITY
  申请人：Trustees of boston College

  公开号：US20150239936A1

  公开（公告）日：2015-08-27

  Described herein are antimicrobial peptides for use in pharmaceutical antibiotic compositions and methods of use thereof. These antimicrobial peptides are Gramicidin A (gA) peptide analogs that, in addition to having potent anti-microbial activity, have greatly increased solubility and significantly reduced toxicity in comparison to the wild-type Gramicidin A peptide.

  本文描述了用于制药抗生素组合物中的抗菌肽及其使用方法。这些抗菌肽是革兰氏阴性杆菌A（gA）肽类似物，除了具有强大的抗微生物活性外，与野生型革兰氏阴性杆菌A肽相比，它们具有极大的溶解性和显著降低的毒性。
• Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics
  申请人：PRESIDENT AND FELLOWS OF HARVARD COLLEGE

  公开号：US10000756B2

  公开（公告）日：2018-06-19

  The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.

  本发明提供了调节微RNA（miRNA）生物发生的组合物和方法。本发明还涉及用于治疗或预防癌症的组合物和方法。
• Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
  申请人：THE CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10273283B2

  公开（公告）日：2019-04-30

  Described herein are modified integrin α and/or β headpiece polypeptides, and crystallizable integrin polypeptide dimers comprising a modified integrin α and/or β headpiece polypeptide and a disulfide bond linking the two integrin headpiece polypeptide subunits. Methods for using the modified integrin α and/or β headpiece polypeptides and the integrin polypeptide dimers are also provided herein. For example, methods for characterizing integrin-ligand interaction and identifying integrin ligands are also provided herein. In some embodiments, the identified integrin ligands can be used as inhibitors of integrins.

  本文描述了修饰的整合素α和/或β头多肽，以及可结晶的整合素多肽二聚体，其包含修饰的整合素α和/或β头多肽和连接两个整合素头多肽亚基的二硫键。本文还提供了使用修饰的整合素α和/或β头多肽和整合素多肽二聚体的方法。例如，本文还提供了表征整合素-配体相互作用和鉴定整合素配体的方法。在某些实施方案中，鉴定出的整合素配体可用作整合素的抑制剂。
• GROWTH HORMONE SECRETATOGUE RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：The Administrators of the Tulane Educational Fund

  公开号：EP2582715B1

  公开（公告）日：2018-11-28